Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cannabidiol Solution for Behavioral Symptoms in MCI or Alzheimer's Dementia
NCT04075435Phase 1Active, not recruiting
- Sponsor
- McLean Hospital
- Start
- Jan 2021
- Primary completion
- Dec 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of cannabidiol in anxiety disorder and agitation, sponsored by McLean Hospital. Primary endpoint: Neuropsychiatric Inventory Clinician Impression Anxiety Domain Score. Started Jan 2021; status: active, not recruiting.
02
Drugs
cannabidiol
03
Conditions
anxiety disorderagitation
Beyond the preview
Go deeper on NCT04075435.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04075435.